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What is it?  Muscular dystrophy (MD)
is a group of inherited muscle
diseases that cause wasting and
weakness of the muscles.
Not to be confused with…  MND
(motor neurone disease), MS
(multiple sclerosis), SMA (spinal
muscular atrophy), or any other
neurological acronym with an M in it.
Is muscular dystrophy all one thing?
No. It’s long been clear that these
disorders are heterogeneous, varying
in age of onset, severity, pattern of
muscle involvement and inheritance.
In the past, useful classifications have
been produced but these were always
to some extent arbitrary and therefore
controversial. The field was rife with
nosological debate.
Are things clearer now?  Yes. A
breakthrough came in 1987 when
the causative gene for the most
common severe form of MD,
Duchenne muscular dystrophy
(DMD — the field is rich in
eponyms, too) was found. Since then,
the genes affected in many MDs
have been discovered, enabling
classification and diagnosis to be put
on a much more secure footing.
Some traditional disease categories
have split as a result (recessive limb
girdle muscular dystrophy —
LGMD — now has eight subtypes),
whereas others have merged. The
flood of genes and gene products has
provided much opportunity for new
names including the protein that is
missing in Fukuyama dystrophy
(another eponym), memorably called
Fukutin.
Is this just so much stamp collecting?
No. These changes to the
classification allow physicians to offer
more accurate prognosis and
antenatal diagnosis. Better still, they
give biological insight and may lead
to therapy.
Are all the disease genes known?  No.
For several diseases there are only
linked loci. Especially interesting is
fascioscapulohumeral dystrophy
(mercifully, known as FSHD).
FSHD is associated with specific
deletions of chromosome 4q35 but
no genes have been found in the
region. Perhaps the deletion changes
the structure of a neighbouring
chromosomal region and alters
transcription there (a ‘position
effect’). Indeed, alterations in
expression of several muscle-specific
messenger RNAs have been found
recently in FSHD.
So, has identifying the genes explained
what goes wrong in dystrophic muscle?
Not completely. Take DMD, for
example. Dystrophin, the protein
product of the mutated gene,
normally sits at the muscle cell
membrane but is lost in DMD.
Several binding partners of
dystrophin have been identified.
The amino-terminal of dystrophin
interacts with F-actin, part of the
cellular cytoskeleton. The other end
of dystrophin at the cell membrane
binds a group of glycoproteins
collectively known as the
dystrophin-associated protein
complex (DAPC). Among these are
four sarcoglycans and dystoglycan,
which binds via its extracellular
portion to laminin-α2, a component
of the extracellular matrix.
Dystrophin thus links the internal
structure of the muscle cell with the
external matrix. Cells deficient in
dystrophin are particularly prone to
membrane damage from physical
stresses, so a natural hypothesis is
that dystrophin is an important
structural component supporting the
membrane. Fitting well with this, it
turned out that mutations in the
sarcoglycans and laminin-α2 all cause
forms of MD. All looked good for the
structural hypothesis, which attracted
a catchphrase: ‘Dystrophin is a
rubber band’.
Is there a bad joke in the offing?  Yes.
Recent findings have put the
hypothesis under strain and
stretched it to breaking point.
Indeed, it may not bounce back.
So it isn’t a structural component? Well,
it’s not that straightforward.
Dystrophin also binds α-dystrobrevin
and, like several other components of
the DAPC, α-dystrobrevin is lost from
the membrane in DMD. Now,
α-dystrobrevin knockout mice have
been made. In these mice, dystrophin
and the other elements of the
putative intracellular–extracellular
link are all intact, yet the mice still
have muscular dystrophy.
Is there any progress in curing these
diseases?  MD is a favourite of gene
therapists. Preliminary studies using
an adeno-associated virus to replace
γ-sarcoglycan in patients with
LGMD 2C have just started. One
(non gene therapy) strategy for
DMD is to upregulate utrophin (an
autosomal homologue of dystrophin).
Transgenic mice deficient in
dystrophin but overexpressing
utrophin in muscle are spared MD.
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